NCT06157151Phase 2Recruiting

PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

Study sponsor: Precigen, Inc · PGEN

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-11-11Estimated
Enrollment · participants24Estimated
Source updated2026-04-23Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab or pembrolizumab alone in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer.. After: Measure: Determine the Objective Response Rate (ORR) following treatment with PRGN-2009 in combination with pembrolizumab in patients with pembrolizumab-resistant recurrent or metastatic cervical cancer..

Planned enrollment decreased by 22 participants

Before: 46 participants (planned). After: 24 participants (planned).

Primary completion date changed

Before: 30 Jan 2028. After: 11 Nov 2026.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview